First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test (Guardant Health)

The National Cancer Institute has enrolled the first patient in its Vanguard Study to evaluate Guardant Health’s Shield™ multi-cancer detection (MCD) blood test, which can screen for multiple cancers—including colorectal, lung, breast, prostate, pancreatic, liver, ovarian, gastric, esophageal, and bladder cancers—from a single blood draw. With plans to enroll up to 24,000 participants over four years, the study aims to assess the feasibility and impact of using MCD tests in large-scale cancer screening trials. Shield has already received FDA Breakthrough Device Designation, positioning it as a potential game-changer for early detection in average-risk individuals.